News for BioCardia, Inc. (BCDAW)

SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardi

BioCardia (BCDA) CEO to discuss key innovations at A.G.P. Virtual Healthcare Company Showcase. Focus on CardiAMP, a leading autologous cell therapy for

Release Date: May 14, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points BioCardia Inc (BC

Start Time: 16:30 January 1, 0000 5:01 PM ETBioCardia, Inc.

**media[620828]**

BioCardia (BCDA) has announced a new development in its Phase 3 CardiAMP HF II trial, with the University of Wisconsin in Madison now enlisting patients affecte

CardiAMP HF II is Evaluating the CardiAMPâ„¢ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) and Ele

**media[615891]**

SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [ BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of ca

India-based Zoomcar Holdings, Inc. (ZCAR) is up over 123 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

US stock market today is swinging between gains and losses as investors react to Big Tech earnings and Trumps latest tariff news. The S&P 500, Dow Jones, and Nasdaq are all feeling the heat, while stocks like Apple, Microsoft, and Amazon—part of the Magnificent Seven—could shift market momentum. With futures wavering and sectors responding differently, traders are staying cautious. This is your one-stop update on top gainers, market trends, and whats moving Wall Street right now.

CardiAMP HF II is Evaluating the CardiAMPâ„¢ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Ma

BioCardia, Inc. (BCDA) has initiated patient enrollment at Emory University School of Medicine in Atlanta, Georgia for its pivotal Phase III CardiAMP HF II stud

BioCardia (BCDA) has started patient enrollment at Emory University School of Medicine for its CardiAMP HF II Phase III trial. The trial aims to evaluat

**media[592649]**

Company positions for long-term growth in medical device markets Salt Lake City, UT, April 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. ( SINT), an

BioCardia, Inc. (NASDAQ:BCDA) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsMiranda Peto - Investor RelationsPeter Altman -...

**media[581871]**

**media[577781]**